Allergan play gooses Revance

|About: Revance Therapeutics, ... (RVNC)|By:, SA News Editor

Traders apparently believe the potential acquisition of Allergan by Valeant and Pershing Square bodes well for Revance Therapeutics (RVNC). Shares are up 20% premarket on mediocre volume.

After yesterday's close, the company announced positive results from it Phase 1/2 clinical trial for RT002 injectable botulinum toxin type A for the treatment of moderate to severe glabellar (frown) lines. Its patented TransMTS technology is designed to provide a longer duration of effect.